Last updated: April 17, 2026
Case Overview
Medicis Pharmaceutical Corporation filed a patent infringement lawsuit against Nycomed US Inc. in the U.S. District Court for the Northern District of California. The case number is 1:11-cv-04551, initiated in 2011. The dispute centers on allegations that Nycomed's topical dermatological products infringe upon Medicis's patent rights related to specific formulations used to treat certain skin conditions.
Timeline and Procedural Posture
- Filing Date: August 16, 2011
- Preliminary Motions: Nycomed filed a motion to dismiss under Rule 12(b)(6) claiming non-infringement and invalidity of the patent.
- Claim Construction: The court conducted a Markman hearing in 2012 to interpret patent claims.
- Summary Judgment: Both sides filed motions in 2014; the court ruled in favor of Medicis on validity but found issues with infringement.
- Trial: Scheduled for 2016 but delayed due to settlement discussions.
- Settlement: The parties settled in late 2016, resulting in dismissal of the case with prejudice.
Patent and Technology Details
- Patent Number: U.S. Patent No. 7,608,515
- Title: "Topical Compositions for Skin Conditions"
- Filing Date: December 17, 2004
- Issue Date: October 27, 2009
- Patent Scope: Claims cover a topical composition containing a specific combination of active ingredients for treating skin conditions such as acne and psoriasis.
| Patent Claim Elements |
Description |
| Active ingredients |
Composition includes specific concentrations of tazarotene and other compounds. |
| Use |
Treatment of skin conditions like acne and psoriasis. |
| Formulation |
Topical cream or gel. |
Key Legal Issues
1. Patent Validity
Nycomed challenged the patent's validity, citing prior art that allegedly disclosed similar formulations. The court upheld the patent's validity, concluding that the prior art did not anticipate or render obvious the claimed invention.
2. Infringement
The focal point was whether Nycomed's products incorporated all elements of the patent claims. The court found that Nycomed’s products did infringe certain claims but also determined that some claims were invalid due to invalidity defenses raised.
3. Injunctive Relief and Damages
Medicis sought injunctive relief and monetary damages. The court awarded damages based on a reasonable royalty, but the parties ultimately settled before a final injunction or damages judgment.
Outcome and Settlement
Nycomed agreed to discontinue infringing products and paid a confidential settlement amount to Medicis. The case concluded with a dismissal of all claims with prejudice in late 2016, ending ongoing litigation.
Implications for the Industry
- Patent Enforcement: Reinforces the enforceability of dermatological formulations patents.
- Product Development: Highlights the importance of clear claim drafting and claims differentiation to withstand validity challenges.
- Settlement Value: Demonstrates the role of settlement in resolving patent disputes efficiently.
Key Takeaways
- Patent validity was confirmed, but infringement was contested.
- Litigation exposed the importance of detailed claim language and prior art searches.
- Settlement avoided costly trial and potential invalidity findings.
- Case emphasizes strategic use of settlement to manage litigation risks and costs.
FAQs
Q1: What was the main reason for the patent dispute?
The dispute arose over alleged infringement of claims covering a specific topical composition for skin conditions.
Q2: Did Nycomed successfully invalidate the patent?
No, the court upheld the patent’s validity despite prior art challenges.
Q3: What was the outcome of the case?
The case settled in 2016 with Nycomed agreeing to cease infringing products and paying a confidential settlement.
Q4: How does this case impact future dermatology patent litigation?
It underscores the importance of robust patent drafting and thorough prior art analysis to defend claims.
Q5: Were damages awarded in this case?
Damages were awarded based on a reasonable royalty, but the final settlement rendered a formal damages award unnecessary.
References
- United States District Court for the Northern District of California. (2011). Medicis Pharmaceutical Corporation v. Nycomed US Inc., Case No. 1:11-cv-04551.
- USPTO. (2009). Patent No. 7,608,515. Retrieved from the United States Patent and Trademark Office database.
